Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.62 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.52 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.52 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24996834 | 0.85 | CA2 (0.45) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL14309780 | 0.77 | ENPP2 (0.52) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL15459223 | 0.77 | CA2 (0.60) | ENPP2TSHRCA2LPLLIPG | |
| SCHEMBL1138482 | 0.77 | TRPV6 (0.80) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL28166 | 0.77 | ENPP2 (1.00) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL12330470 | 0.74 | ENPP2 (0.60) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL27648777 | 0.74 | ENPP2 (0.94) | ENPP2ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL12212599 | 0.74 | ORAI1 (0.65) | ORAI1ORAI2ORAI3TRPV6LMNA | |
| SCHEMBL1138738 | 0.74 | ORAI1 (0.65) | ORAI1ORAI2ORAI3TRPV6CES2 | |
| SCHEMBL28117303 | 0.74 | ENPP2 (0.94) | ENPP2ORAI1ORAI2ORAI3TRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3369719-B1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2020-02-26 | — | — | EP | disclosed |
| EP-2796448-B1 | Material for organic electronic device and organic electronic device using the same | LG CHEMICAL LTD (KR) | 2018-04-25 | — | — | EP | disclosed |
| US-20160354351-A1 | SOLID STATE FORMS OF VEMURAFENIB HYDROCHLORIDE | RATIOPHARM GMBH (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160354351-A1 | SOLID STATE FORMS OF VEMURAFENIB HYDROCHLORIDE | RATIOPHARM GMBH (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9278946-B2 | Small molecule catalyst for 5-hydroxymethylfurfural production from saccharides | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-03-08 | — | — | US | disclosed |
| US-20150166499-A1 | SMALL MOLECULE CATALYST FOR 5-HYDROXYMETHYLFURFURAL PRODUCTION FROM SACCHARIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-06-18 | — | — | US | disclosed |
| EP-1765358-B1 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7888356-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| CN-101928295-A | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS INC | 2010-12-29 | — | — | CN | disclosed |
| US-7652000-B2 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1765360-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006085932-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| CN-1738802-A | Antibiotics containing boronic acid complexes and methods of use | ANACOR PHARMACEUTICALS INC (US) | 2006-02-22 | — | — | CN | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060009422-A1 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005123094-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166499-A1 | SMALL MOLECULE CATALYST FOR 5-HYDROXYMETHYLFURFURAL PRODUCTION FROM SACCHARIDES | FBP1, UGDH, BLVRB | ENPP2 2812/4885ORAI1 4775/4885ORAI2 4410/4885 |
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | ENPP2 986/4885ORAI1 2189/4885ORAI2 2748/4885 |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | ENPP2 67/4885ORAI1 268/4885ORAI2 367/4885 |
| US-20060009422-A1 | Boron-containing compounds and methods of use | BROX, BTD, PBDC1 | ENPP2 1788/4885ORAI1 2751/4885ORAI2 3905/4885 |
| US-20160354351-A1 | SOLID STATE FORMS OF VEMURAFENIB HYDROCHLORIDE | BRAF, PRPF19, PRPF8 | ENPP2 4804/4885ORAI1 3655/4885ORAI2 4189/4885 |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | ENPP2 986/4885ORAI1 2189/4885ORAI2 2748/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | ENPP2 420/4885ORAI1 1634/4885ORAI2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.